Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the development and commercialization of products for hormone receptor-dependent conditions. Founded in the mid-2000s and publicly listed on the TSX Venture Exchange with an OTCMKTS listing under the ticker TRLPF, Acerus has built a product portfolio centered on hormone therapies. The company’s lead product, Trelstar (triptorelin pamoate), is indicated for advanced prostate cancer and is marketed across the United States, Europe and other international territories under licensing arrangements. In addition to its oncology franchise, Acerus has secured North American rights to Imvexxy, an FDA-approved vaginal estradiol therapy for moderate-to-severe dyspareunia associated with menopause.
Beyond its marketed products, Acerus maintains a development pipeline targeting women’s health and endocrinology. The company is advancing late-stage candidates for conditions such as endometriosis and polycystic ovary syndrome, leveraging its expertise in steroid hormone receptor biology. Acerus partners with contract manufacturing organizations and specialty distributors to ensure consistent supply and broad market access, while exploring strategic collaborations with larger pharmaceutical firms for co-development and licensing opportunities.
Headquartered in Toronto, Canada, Acerus operates commercial and regulatory teams in key markets, including the United States and Europe. The company’s leadership is composed of industry veterans with backgrounds in pharmaceutical research, clinical development and global marketing. Under the guidance of its board of directors, which brings together experience in oncology, endocrinology and corporate finance, Acerus continues to refine its strategic focus on hormone-modulating therapies for underserved patient populations.
Over its history, Acerus has evolved from a small biotech start-up to a commercial-stage specialty pharmaceutical company by executing disciplined product launches and pursuing targeted acquisitions. The firm remains committed to expanding its therapeutic reach through both in-house development and external partnerships, aiming to address unmet medical needs in hormone-related diseases. As it moves forward, Acerus seeks to leverage its proven commercial infrastructure and clinical expertise to bring novel treatments to market and enhance patient care worldwide.
AI Generated. May Contain Errors.
Free TRLPF Stock Alerts